MTEM Molecular Templates Inc.

12.24
+0.4  (+3%)
Previous Close 11.84
Open 12.04
Price To Book 8.56
Market Cap 452,494,562
Shares 36,968,510
Volume 265,268
Short Ratio
Av. Daily Volume 252,326
Stock charts supplied by TradingView

NewsSee all news

  1. Molecular Templates to Present at Two December Investor Conferences

    AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  2. Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

    AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM) (the "Company" or "Molecular"), a clinical-stage biopharmaceutical company focused on the discovery and development of the

  3. Molecular Templates, Inc. Announces Proposed Public Equity Offering

    AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM) (the "Company" or "Molecular"), a clinical-stage biopharmaceutical company focused on the discovery and development of the

  4. Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

    -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE

  5. Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111

    EDMONTON, Alberta, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 update due 4Q 2019.
MT-3724 and chemotherapy
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Development discontinued due to poor data - September 29, 2016.
Tarloxotinib
Cancer - mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer
Phase 3 endpoints not met
Evofosfamide MAESTRO
Cancer - Pancreatic
Phase 3 endpoints not met
Evofosfamide
Cancer - soft tissue sarcoma (406 trial)
Independent Data Safety Monitoring Board conducted unlikely to reach primary endpoint - trial closed
Evofosfamide
Cancer - second line NSCLC
Development discontinued due to poor data - September 29, 2016.
Tarloxotinib
Cancer - Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
Phase 2 update due 4Q 2019.
MT-3724 and Revlimid
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 update due 4Q 2019.
MT-3724
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 update due 4Q 2019.
MT-5111
HER2-positive solid tumors
Phase 1 trial to be initiated 4Q 2019.
TAK-169

Latest News

  1. Molecular Templates to Present at Two December Investor Conferences

    AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  2. Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

    AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM) (the "Company" or "Molecular"), a clinical-stage biopharmaceutical company focused on the discovery and development of the

  3. Molecular Templates, Inc. Announces Proposed Public Equity Offering

    AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM) (the "Company" or "Molecular"), a clinical-stage biopharmaceutical company focused on the discovery and development of the

  4. Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

    -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE

  5. Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111

    EDMONTON, Alberta, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with

  6. Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results

    AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular, " "Molecular Templates" or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and

  7. Molecular Templates Hosting Analyst & Investor Meeting

    AUSTIN, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company's proprietary engineered

  8. Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences

    AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company's proprietary engineered